Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups

Published:2023-10 Issue: Volume: Page:
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wong N.Z.H.,Yap D.W.T.,Ong R.J.M.,Zhao J.J.,Chan Y.H.,Tey J.C.S.,Sundar R.,Lim J.S.J.,Dawood S.S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference44 articles.

1. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study;Martín;Eur J Cancer. Jun,2022

2. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer;Slamon;New England Journal of Medicine,2019

3. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer;Hortobagyi;New England Journal of Medicine,2022

4. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study;Im;J Glob Oncol,2019

5. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer;Johnston;npj Breast Cancer,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP